Filing Flows › Harvard Bioscience (HBIO) › R&D spending
Harvard Bioscience (HBIO) R&D spending by quarter
Harvard Bioscience's R&D spending was $2.5M in Q2 2026 (second quarter 2026), +5% from Q1 2026. Over the last 7 quarters it ranged from $2.1M (Q3 2025) to $2.5M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $2.5M | +5% | +12% |
| Q1 2026 | $2.3M | +7% | +0.2% |
| Q4 2025 | $2.2M | +2% | -6% |
| Q3 2025 | $2.1M | -3% | — |
| Q2 2025 | $2.2M | -6% | — |
| Q1 2025 | $2.3M | -0.3% | — |
| Q4 2024 | $2.3M | — | — |
Q2 2026 at a glance
Harvard Bioscience, Q2 2026: revenue $22.7M (+11% year over year), operating margin -4.3%, net loss $2.9M, operating cash flow $325K. The chart follows the revenue to costs, profit and cash.
Questions
What is Harvard Bioscience's R&D spending?
Harvard Bioscience's R&D spending was $2.5M in Q2 2026 (second quarter 2026), +5% from Q1 2026.
How has Harvard Bioscience's R&D spending changed?
Over the last 7 quarters it ranged from $2.1M (Q3 2025) to $2.5M (Q2 2026).